StockData
BLFSNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31

BIOLIFE SOLUTIONS INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$38.61+0.00 (0.00%)

Close on Oct 7, 2026

Market cap
$1.90B
P/E (TTM)
33.6
Dividend yield
–

Earnings

Next report expected Nov 5, 2026, after market close (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 6, 2026After market close$28.50M––
Q1 FY2026
Ended Mar 31, 2026
May 7, 2026After market close$27.50M$0.02–
Q4 FY2025
Ended Dec 31, 2025
Feb 26, 2026After market close$24.80M$0.04–
Q3 FY2025
Ended Sep 30, 2025
Nov 6, 2025After market close$28.10M$0.01–
Q2 FY2025
Ended Jun 30, 2025
Aug 7, 2025After market close$25.40M$-0.33–
Q1 FY2025
Ended Mar 31, 2025
May 8, 2025After market close$23.90M$-0.01–
Q3 FY2024
Ended Sep 30, 2024
Nov 12, 2024After market close$30.60M$-0.04–
Q2 FY2024
Ended Jun 30, 2024
Aug 8, 2024After market close$28.30M$-0.16–
Q1 FY2024
Ended Mar 31, 2024
May 9, 2024After market close–––
Q4 FY2023
Ended Dec 31, 2023
Jan 8, 2024Before market open–––
Q3 FY2023
Ended Sep 30, 2023
Oct 23, 2023After market close–––

Company guidance

Outlook given with results on May 7, 2026, compared with the previous outlook

MeasurePeriodGuidancevs. prior
growth202617% to 20% growthNew
Revenue2026$112.50M to $115.00MNew

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Biolife Solutions filed with the SEC